250,000 Shares in PepGen, Inc. $PEPG Purchased by Boxer Capital Management LLC

Boxer Capital Management LLC acquired a new stake in PepGen, Inc. (NASDAQ:PEPG) in the 3rd quarter, HoldingsChannel.com reports. The firm acquired 250,000 shares of the company’s stock, valued at approximately $1,155,000. PepGen makes up about 0.4% of Boxer Capital Management LLC’s investment portfolio, making the stock its 29th largest position.

Other hedge funds have also recently modified their holdings of the company. Rangeley Capital LLC lifted its position in shares of PepGen by 133.3% during the 2nd quarter. Rangeley Capital LLC now owns 35,000 shares of the company’s stock worth $39,000 after buying an additional 20,000 shares in the last quarter. Marshall Wace LLP bought a new position in shares of PepGen in the second quarter valued at approximately $44,000. Burkehill Global Management LP purchased a new stake in shares of PepGen during the third quarter valued at approximately $46,000. Qube Research & Technologies Ltd purchased a new stake in shares of PepGen during the second quarter valued at approximately $81,000. Finally, Bridgeway Capital Management LLC lifted its holdings in PepGen by 61.5% during the second quarter. Bridgeway Capital Management LLC now owns 91,923 shares of the company’s stock worth $102,000 after acquiring an additional 35,000 shares during the period. Institutional investors own 58.01% of the company’s stock.

Wall Street Analysts Forecast Growth

PEPG has been the topic of several research analyst reports. Oppenheimer assumed coverage on PepGen in a research report on Wednesday, February 25th. They issued an “outperform” rating and a $15.00 price objective on the stock. Wall Street Zen raised PepGen from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Guggenheim boosted their price target on shares of PepGen from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of PepGen in a research report on Thursday, January 22nd. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, PepGen presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.60.

PepGen Trading Down 13.5%

Shares of NASDAQ PEPG opened at $5.32 on Friday. The stock has a fifty day simple moving average of $5.85 and a two-hundred day simple moving average of $4.92. PepGen, Inc. has a 1-year low of $0.88 and a 1-year high of $7.80. The firm has a market cap of $367.67 million, a price-to-earnings ratio of -2.21 and a beta of 1.87.

PepGen (NASDAQ:PEPG) last issued its earnings results on Wednesday, March 4th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.13. Analysts forecast that PepGen, Inc. will post -2.73 EPS for the current year.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).